Amanda Griggs

Cooley advised Machinify, a provider of artificial intelligence-powered software transforming healthcare payments, on its definitive agreement to be acquired by New Mountain Capital.

Cooley advised Machinify, a provider of artificial intelligence-powered software transforming healthcare payments, on its definitive agreement to be acquired by New Mountain Capital.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Expert Institute (EI), a provider of outsourced legal services to the attorney market, on its acquisition by Levine Leichtman Capital Partners, a Los Angeles-based private equity firm, from Spectrum Equity, a growth equity firm that provides capital and strategic support to innovative companies in the information economy, in partnership with management.

Cooley advised Lacework, a data-driven cloud security company, on its definitive agreement to be acquired by Fortinet (Nasdaq: FTNT), the global cybersecurity leader driving the convergence of networking and security.